S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
NASDAQ:AIMT

Aimmune Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$34.49
0.00 (0.00 %)
(As of 10/13/2020)
Add
Compare
Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
VolumeN/A
Average Volume1.71 million shs
Market Capitalization$2.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aimmune Therapeutics logo

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AIMT
Employees
228
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.66 per share

Profitability

Net Income
$-248.50 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.26 billion
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

988th out of 1,361 stocks

Pharmaceutical Preparations Industry

480th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What stocks does MarketBeat like better than Aimmune Therapeutics?

Wall Street analysts have given Aimmune Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aimmune Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.06).
View Aimmune Therapeutics' earnings history
.

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the following people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $34.49.

How much money does Aimmune Therapeutics make?

Aimmune Therapeutics has a market capitalization of $2.26 billion. The biotechnology company earns $-248.50 million in net income (profit) each year or ($3.97) on an earnings per share basis.

How many employees does Aimmune Therapeutics have?

Aimmune Therapeutics employs 228 workers across the globe.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is www.aimmune.com.

Where are Aimmune Therapeutics' headquarters?

Aimmune Therapeutics is headquartered at 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.